DK3035955T3 - Sammensætning og vaccine til behandling af lungekræft - Google Patents

Sammensætning og vaccine til behandling af lungekræft Download PDF

Info

Publication number: DK3035955T3
Authority: DK; Denmark
Prior art keywords: vaccine; treatment; composition; lung cancer; lung
Prior art date: 2013-08-21

Application number

DK14755334T

Other languages

English (en)

Inventor

Karl-Josef Kallen

Mariola Fotin-Mleczek

Ulrike Gnad-Vogt

Original Assignee

Curevac Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-21

Filing date

2014-08-21

Publication date

2019-12-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49003746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3035955(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-21 Application filed by Curevac Ag filed Critical Curevac Ag

2019-12-02 Application granted granted Critical

2019-12-02 Publication of DK3035955T3 publication Critical patent/DK3035955T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK14755334T 2013-08-21 2014-08-21 Sammensætning og vaccine til behandling af lungekræft DK3035955T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2013002514		2013-08-21
PCT/EP2014/002299 WO2015024666A1 (en)	2013-08-21	2014-08-21	Composition and vaccine for treating lung cancer

Publications (1)

Publication Number	Publication Date
DK3035955T3 true DK3035955T3 (da)	2019-12-02

Family

ID=49003746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14755334T DK3035955T3 (da)	2013-08-21	2014-08-21	Sammensætning og vaccine til behandling af lungekræft

Country Status (22)

Country	Link
US (1)	US20160168227A1 (da)
JP (1)	JP6678582B2 (da)
KR (1)	KR20160042935A (da)
CN (1)	CN105530952A (da)
AP (1)	AP2016009090A0 (da)
AU (2)	AU2014310932B2 (da)
BR (1)	BR112016003400A2 (da)
CA (1)	CA2914508A1 (da)
CL (1)	CL2016000388A1 (da)
DK (1)	DK3035955T3 (da)
EA (1)	EA037217B1 (da)
ES (1)	ES2759910T3 (da)
HU (1)	HUE046469T2 (da)
IL (2)	IL243090B (da)
MX (1)	MX369154B (da)
MY (1)	MY174677A (da)
PE (1)	PE20160224A1 (da)
PH (1)	PH12015502718A1 (da)
SG (2)	SG11201510748PA (da)
UA (1)	UA120595C2 (da)
WO (1)	WO2015024666A1 (da)
ZA (1)	ZA201508947B (da)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8877206B2 (en)	2007-03-22	2014-11-04	Pds Biotechnology Corporation	Stimulation of an immune response by cationic lipids
WO2009129227A1 (en)	2008-04-17	2009-10-22	Pds Biotechnology Corporation	Stimulation of an immune response by enantiomers of cationic lipids
WO2012019630A1 (en)	2010-08-13	2012-02-16	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en)	2011-03-02	2012-09-07	Curevac Gmbh	Vaccination in elderly patients
CA3198966A1 (en)	2011-06-08	2012-12-13	Translate Bio, Inc.	Cleavable lipids
WO2013120497A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
ES2969742T3 (es)	2012-03-27	2024-05-22	CureVac SE	Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
CN105163753B (zh)	2012-06-15	2018-12-21	Pds生物科技公司	阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en)	2012-09-21	2016-05-04	Frank Bedu-Addo	IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
US9974845B2 (en)	2013-02-22	2018-05-22	Curevac Ag	Combination of vaccination and inhibition of the PD-1 pathway
ES2747762T3 (es)	2013-08-21	2020-03-11	Curevac Ag	Vacuna contra el virus respiratorio sincitial (RSV)
CN110195072A (zh)	2013-08-21	2019-09-03	库瑞瓦格股份公司	狂犬病疫苗
CN105473157A (zh)	2013-08-21	2016-04-06	库瑞瓦格股份公司	组合疫苗
KR102354389B1 (ko)	2013-08-21	2022-01-20	큐어백 아게	Rna―암호화된 단백질의 발현을 증가시키는 방법
ES2806575T3 (es)	2013-11-01	2021-02-18	Curevac Ag	ARN modificado con propiedades inmunoestimuladoras disminuidas
JP6584414B2 (ja)	2013-12-30	2019-10-02	キュアバックアーゲー	人工核酸分子
SG11201604198YA (en)	2013-12-30	2016-07-28	Curevac Ag	Methods for rna analysis
ES2754239T3 (es)	2014-03-12	2020-04-16	Curevac Ag	Combinación de vacunación y agonistas de OX40
WO2015149944A2 (en)	2014-04-01	2015-10-08	Curevac Gmbh	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
BR112016026980B1 (pt)	2014-06-10	2022-05-03	Curevac Real Estate Gmbh	Método para sintetizar uma molécula de rna de uma dada sequência
JP2017536347A (ja) *	2014-10-17	2017-12-07	ノバルティスアーゲー	セリチニブとｅｇｆｒ阻害剤の組合せ
DK4023755T5 (da)	2014-12-12	2024-07-29	CureVac SE	Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
WO2016165825A1 (en)	2015-04-13	2016-10-20	Curevac Ag	Method for producing rna compositions
US10780054B2 (en)	2015-04-17	2020-09-22	Curevac Real Estate Gmbh	Lyophilization of RNA
AU2016251687C1 (en)	2015-04-22	2023-07-27	CureVac SE	RNA containing composition for treatment of tumor diseases
EP3289083A4 (en)	2015-04-27	2018-12-19	The Trustees Of The University Of Pennsylvania	Nucleoside-modified rna for inducing an adaptive immune response
SG11201708867UA (en)	2015-04-30	2017-11-29	Curevac Ag	Immobilized poly(n)polymerase
EP3294885B1 (en)	2015-05-08	2020-07-01	CureVac Real Estate GmbH	Method for producing rna
DK3294326T3 (da)	2015-05-15	2021-05-31	Curevac Ag	Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
US10517827B2 (en)	2015-05-20	2019-12-31	Curevac Ag	Dry powder composition comprising long-chain RNA
US10729654B2 (en)	2015-05-20	2020-08-04	Curevac Ag	Dry powder composition comprising long-chain RNA
EP4098743A1 (en)	2015-05-29	2022-12-07	CureVac AG	Method for adding cap structures to rna using immobilized enzymes
WO2016193206A1 (en)	2015-05-29	2016-12-08	Curevac Ag	A method for producing and purifying rna, comprising at least one step of tangential flow filtration
WO2016201377A1 (en) *	2015-06-10	2016-12-15	Moderna Therapeutics, Inc.	Targeted adaptive vaccines
CN107849565A (zh) *	2015-06-30	2018-03-27	埃泽瑞斯公司	Atp结合盒家族的编码多核糖核苷酸及其制剂
WO2017009376A1 (en)	2015-07-13	2017-01-19	Curevac Ag	Method of producing rna from circular dna and corresponding template dna
CN114381470A (zh)	2015-08-28	2022-04-22	库瑞瓦格股份公司	人工核酸分子
DK3350157T3 (da)	2015-09-17	2022-02-14	Modernatx Inc	Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
EP3362576A1 (en)	2015-10-12	2018-08-22	CureVac AG	Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066791A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Sugar substituted mrna cap analogs
WO2017066782A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Hydrophobic mrna cap analogs
WO2017066789A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Mrna cap analogs with modified sugar
DK3362461T3 (da)	2015-10-16	2022-05-09	Modernatx Inc	Mrna-cap-analoger med modificeret phosphatbinding
AU2016340183A1 (en)	2015-10-16	2018-04-19	Modernatx, Inc.	mRNA cap analogs and methods of mRNA capping
US11413346B2 (en)	2015-11-09	2022-08-16	Curevac Ag	Rotavirus vaccines
CA3005251A1 (en)	2015-11-13	2017-05-18	Pds Biotechnology Corporation	Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
AU2016377681B2 (en)	2015-12-22	2021-05-13	Modernatx, Inc.	Compounds and compositions for intracellular delivery of agents
US11684665B2 (en)	2015-12-22	2023-06-27	CureVac SE	Method for producing RNA molecule compositions
US11248223B2 (en)	2015-12-23	2022-02-15	Curevac Ag	Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
MX2018009917A (es)	2016-02-17	2019-08-14	Curevac Ag	Vacuna contra el virus del zika.
US11920174B2 (en)	2016-03-03	2024-03-05	CureVac SE	RNA analysis by total hydrolysis and quantification of released nucleosides
WO2017186928A1 (en)	2016-04-29	2017-11-02	Curevac Ag	Rna encoding an antibody
EP3452101A2 (en)	2016-05-04	2019-03-13	CureVac AG	Rna encoding a therapeutic protein
EP4477662A3 (en)	2016-05-04	2025-03-19	CureVac SE	Nucleic acid molecules and uses thereof
EP3468613A1 (en)	2016-06-09	2019-04-17	CureVac AG	Hybrid carriers for nucleic acid cargo
CA3029813A1 (en)	2016-06-13	2017-12-21	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
AU2017286606A1 (en)	2016-06-14	2018-12-13	Modernatx, Inc.	Stabilized formulations of lipid nanoparticles
US11583504B2 (en)	2016-11-08	2023-02-21	Modernatx, Inc.	Stabilized formulations of lipid nanoparticles
US11279923B2 (en)	2016-11-28	2022-03-22	Curevac Ag	Method for purifying RNA
AU2017368050A1 (en)	2016-11-29	2019-06-20	Puretech Lyt, Inc.	Exosomes for delivery of therapeutic agents
WO2018104538A1 (en)	2016-12-08	2018-06-14	Curevac Ag	Rna for treatment or prophylaxis of a liver disease
US11542490B2 (en)	2016-12-08	2023-01-03	CureVac SE	RNAs for wound healing
EP3558356A2 (en)	2016-12-23	2019-10-30	CureVac AG	Mers coronavirus vaccine
EP3558354A1 (en)	2016-12-23	2019-10-30	CureVac AG	Lassa virus vaccine
EP3558355A2 (en)	2016-12-23	2019-10-30	CureVac AG	Henipavirus vaccine
US11241490B2 (en)	2017-01-11	2022-02-08	The Trustees Of The University Of Pennsylvania	Nucleoside-modified RNA for inducing an immune response against zika virus
EP3589308A1 (en)	2017-02-28	2020-01-08	Sanofi	Therapeutic rna
AU2018234692B2 (en)	2017-03-15	2022-06-02	Modernatx, Inc.	Compounds and compositions for intracellular delivery of therapeutic agents
CA3055653A1 (en)	2017-03-15	2018-09-20	Modernatx, Inc.	Lipid nanoparticle formulation
CN110392577A (zh)	2017-03-17	2019-10-29	库尔维科公司	用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
US11739335B2 (en)	2017-03-24	2023-08-29	CureVac SE	Nucleic acids encoding CRISPR-associated proteins and uses thereof
US11357856B2 (en)	2017-04-13	2022-06-14	Acuitas Therapeutics, Inc.	Lipids for delivery of active agents
WO2018211038A1 (en)	2017-05-17	2018-11-22	Curevac Ag	Method for determining at least one quality parameter of an rna sample
WO2018232120A1 (en)	2017-06-14	2018-12-20	Modernatx, Inc.	Compounds and compositions for intracellular delivery of agents
US10988754B2 (en)	2017-07-04	2021-04-27	Cure Vac AG	Nucleic acid molecules
SG11202000197PA (en) *	2017-07-11	2020-02-27	Pfizer	Immunogenic compositions comprising cea muc1 and tert
US20200362382A1 (en)	2017-08-18	2020-11-19	Modernatx, Inc.	Methods of preparing modified rna
EP3673069A1 (en)	2017-08-22	2020-07-01	CureVac AG	Bunyavirales vaccine
MX2020002348A (es)	2017-08-31	2020-10-08	Modernatx Inc	Métodos de elaboración de nanopartículas lipídicas.
KR20210032924A (ko)	2017-09-05	2021-03-25	토크 테라퓨틱스, 인코포레이티드	치료용 단백질 조성물 및 그의 제조 및 사용 방법
IL321714A (en)	2017-10-19	2025-08-01	CureVac SE	Novel artificial nucleic acid molecules
JP2021502079A (ja)	2017-11-08	2021-01-28	キュアバックアーゲー	ＲＮＡ配列の適合（Ａｄａｐｔａｔｉｏｎ）
EP3723796A1 (en)	2017-12-13	2020-10-21	CureVac AG	Flavivirus vaccine
WO2019122371A1 (en)	2017-12-21	2019-06-27	Curevac Ag	Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
CN108440669B (zh) *	2018-02-09	2021-08-06	焦顺昌	一种融合蛋白及治疗非小细胞肺癌的重组病毒疫苗和制备方法
MX2020008394A (es) *	2018-02-12	2020-09-21	Biontech Rna Pharmaceuticals Gmbh	Tratamiento que usa arn que codifica citoquinas.
EP4227319B1 (en)	2018-04-17	2025-11-26	CureVac SE	Novel rsv rna molecules and compositions for vaccination
IL279759B1 (en)	2018-06-28	2025-10-01	Tesla Automation GmbH	Bioreactor for in vitro RNA transcription
US12263248B2 (en)	2018-09-19	2025-04-01	Modernatx, Inc.	Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en)	2018-09-20	2024-09-17	Modernatx, Inc.	Preparation of lipid nanoparticles and methods of administration thereof
CN110684800B (zh) *	2018-11-02	2020-11-03	深圳益世康宁生物科技有限公司	一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值
SG11202106666UA (en)	2018-12-21	2021-07-29	Curevac Ag	Methods for rna analysis
WO2020160430A1 (en)	2019-01-31	2020-08-06	Modernatx, Inc.	Vortex mixers and associated methods, systems, and apparatuses thereof
BR112021014845A2 (pt)	2019-01-31	2021-11-03	Modernatx Inc	Métodos de preparação de nanopartículas lipídicas
CN110448689A (zh) *	2019-08-06	2019-11-15	太仓美诺恒康生物技术有限公司	mRNA疫苗及其试剂盒、应用
CN110448695B (zh) *	2019-08-23	2021-07-27	中山大学肿瘤防治中心	一种mRNA疫苗递送载体及其制备方法
US12194089B2 (en)	2020-02-04	2025-01-14	CureVac SE	Coronavirus vaccine
US11241493B2 (en)	2020-02-04	2022-02-08	Curevac Ag	Coronavirus vaccine
TW202204622A (zh)	2020-04-09	2022-02-01	大陸商蘇州艾博生物科技有限公司	針對冠狀病毒之核酸疫苗
CN117003658B (zh)	2020-04-09	2025-10-14	苏州艾博生物科技有限公司	脂质纳米颗粒组合物
CA3182994A1 (en)	2020-06-30	2022-01-06	Bo YING	Lipid compounds and lipid nanoparticle compositions
JP2023537887A (ja)	2020-08-20	2023-09-06	スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド	脂質化合物及び脂質ナノ粒子組成物
CA3198708A1 (en) *	2020-11-20	2022-05-27	Frank Bedu-Addo	Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection
MX2023007574A (es)	2020-12-22	2023-09-29	CureVac SE	"vacuna de arn contra variantes de sars-cov-2.
WO2022152109A2 (en)	2021-01-14	2022-07-21	Suzhou Abogen Biosciences Co., Ltd.	Lipid compounds and lipid nanoparticle compositions
CN116615472A (zh)	2021-01-14	2023-08-18	苏州艾博生物科技有限公司	聚合物缀合的脂质化合物和脂质纳米颗粒组合物
KR20240013087A (ko)	2021-05-24	2024-01-30	쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드	지질 화합물 및 지질 나노입자 조성물
EP4402123A1 (en)	2021-09-14	2024-07-24	Renagade Therapeutics Management Inc.	Cyclic lipids and methods of use thereof
EP4402121A1 (en)	2021-09-14	2024-07-24	Renagade Therapeutics Management Inc.	Acyclic lipids and methods of use thereof
AR127312A1 (es)	2021-10-08	2024-01-10	Suzhou Abogen Biosciences Co Ltd	Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
AU2022358824A1 (en)	2021-10-08	2024-04-11	Suzhou Abogen Biosciences Co., Ltd.	Lipid compounds and lipid nanoparticle compositions
CN116064598B (zh)	2021-10-08	2024-03-12	苏州艾博生物科技有限公司	冠状病毒的核酸疫苗
TW202333802A (zh) *	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
US20250108007A1 (en)	2021-12-23	2025-04-03	Suzhou Abogen Biosciences Co., Ltd.	Lipid compound and lipid nanoparticle composition
EP4452928A1 (en)	2021-12-23	2024-10-30	Renagade Therapeutics Management Inc.	Constrained lipids and methods of use thereof
CA3255619A1 (en)	2022-04-07	2023-10-12	Renagade Therapeutics Man Inc	CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
WO2024037578A1 (en)	2022-08-18	2024-02-22	Suzhou Abogen Biosciences Co., Ltd.	Composition of lipid nanoparticles
KR102540330B1 (ko) *	2022-10-19	2023-06-05	엠브릭스 주식회사	인지질인 포스파티딜에탄올아민을 포함하는 나노디스크
WO2024089638A1 (en)	2022-10-28	2024-05-02	Glaxosmithkline Biologicals Sa	Nucleic acid based vaccine
CN116970614A (zh) *	2022-12-29	2023-10-31	达冕疫苗(广州)有限公司	编码ny-eso-1的核糖核酸疫苗的组合物和方法
WO2024192277A2 (en)	2023-03-15	2024-09-19	Renagade Therapeutics Management Inc.	Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
AU2024236558A1 (en)	2023-03-15	2025-10-09	Renagade Therapeutics Management Inc.	Delivery of gene editing systems and methods of use thereof
WO2025049442A1 (en) *	2023-08-28	2025-03-06	H. Lee Moffitt Cancer Center And Research Institute Inc.	Survivin mrna vaccine
WO2025049959A2 (en)	2023-09-01	2025-03-06	Renagade Therapeutics Management Inc.	Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025081042A1 (en)	2023-10-12	2025-04-17	Renagade Therapeutics Management Inc.	Nickase-retron template-based precision editing system and methods of use
WO2025128871A2 (en)	2023-12-13	2025-06-19	Renagade Therapeutics Management Inc.	Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en)	2024-01-17	2025-07-24	Renagade Therapeutics Management Inc.	Improved gene editing system, guides, and methods
WO2025174765A1 (en)	2024-02-12	2025-08-21	Renagade Therapeutics Management Inc.	Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1573058B1 (en) *	2002-12-18	2011-09-14	ChromaGenics B.V.	A method for improving protein production
DK1776460T3 (da) *	2004-08-03	2010-04-12	Geneart Ag	Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet
US8249451B2 (en) *	2007-08-16	2012-08-21	Futurewei Technologies, Inc.	Methods for characterizing optical switches and multiplexers/demultiplexers
WO2009046738A1 (en) *	2007-10-09	2009-04-16	Curevac Gmbh	Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) *	2007-10-09	2009-04-16	Curevac Gmbh	Composition for treating prostate cancer (pca)
WO2010037408A1 (en) *	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
GB2484058A (en) *	2009-12-01	2012-04-04	Uni Konstanz	Prostate cancer DNA vaccine
WO2012019630A1 (en) *	2010-08-13	2012-02-16	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) *	2010-12-29	2012-07-05	Curevac Gmbh	Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) *	2011-03-02	2012-09-07	Curevac Gmbh	Vaccination in newborns and infants
WO2012116714A1 (en) *	2011-03-02	2012-09-07	Curevac Gmbh	Vaccination in elderly patients

2014
- 2014-08-21 SG SG11201510748PA patent/SG11201510748PA/en unknown
- 2014-08-21 HU HUE14755334A patent/HUE046469T2/hu unknown
- 2014-08-21 CN CN201480045806.0A patent/CN105530952A/zh active Pending
- 2014-08-21 MY MYPI2015704442A patent/MY174677A/en unknown
- 2014-08-21 UA UAA201602593A patent/UA120595C2/uk unknown
- 2014-08-21 JP JP2016535368A patent/JP6678582B2/ja not_active Expired - Fee Related
- 2014-08-21 PE PE2016000244A patent/PE20160224A1/es unknown
- 2014-08-21 WO PCT/EP2014/002299 patent/WO2015024666A1/en not_active Ceased
- 2014-08-21 SG SG10201801429VA patent/SG10201801429VA/en unknown
- 2014-08-21 DK DK14755334T patent/DK3035955T3/da active
- 2014-08-21 AU AU2014310932A patent/AU2014310932B2/en not_active Ceased
- 2014-08-21 EA EA201600189A patent/EA037217B1/ru not_active IP Right Cessation
- 2014-08-21 CA CA2914508A patent/CA2914508A1/en not_active Abandoned
- 2014-08-21 KR KR1020167005863A patent/KR20160042935A/ko not_active Ceased
- 2014-08-21 BR BR112016003400A patent/BR112016003400A2/pt not_active Application Discontinuation
- 2014-08-21 ES ES14755334T patent/ES2759910T3/es active Active
- 2014-08-21 AP AP2016009090A patent/AP2016009090A0/xx unknown
- 2014-08-21 MX MX2016002151A patent/MX369154B/es active IP Right Grant
2015
- 2015-12-04 PH PH12015502718A patent/PH12015502718A1/en unknown
- 2015-12-08 ZA ZA2015/08947A patent/ZA201508947B/en unknown
- 2015-12-14 IL IL243090A patent/IL243090B/en active IP Right Grant
2016
- 2016-02-19 CL CL2016000388A patent/CL2016000388A1/es unknown
- 2016-02-19 US US15/048,216 patent/US20160168227A1/en not_active Abandoned
2019
- 2019-09-02 AU AU2019226125A patent/AU2019226125B2/en not_active Ceased
2020
- 2020-08-02 IL IL276428A patent/IL276428A/en unknown

Also Published As

Publication number	Publication date
AU2019226125A1 (en)	2019-09-26
MX2016002151A (es)	2016-12-14
EA037217B1 (ru)	2021-02-20
CL2016000388A1 (es)	2016-10-14
MX369154B (es)	2019-10-30
US20160168227A1 (en)	2016-06-16
ZA201508947B (en)	2020-05-27
CN105530952A (zh)	2016-04-27
HK1225987A1 (en)	2017-09-22
AU2014310932A1 (en)	2015-12-24
JP2016528264A (ja)	2016-09-15
MY174677A (en)	2020-05-06
UA120595C2 (uk)	2020-01-10
IL243090B (en)	2020-08-31
CA2914508A1 (en)	2015-02-26
AU2019226125B2 (en)	2021-03-25
PE20160224A1 (es)	2016-05-14
SG11201510748PA (en)	2016-03-30
IL276428A (en)	2020-09-30
BR112016003400A2 (pt)	2017-12-05
AU2014310932B2 (en)	2019-06-06
AP2016009090A0 (en)	2016-03-31
SG10201801429VA (en)	2018-03-28
HUE046469T2 (hu)	2020-03-30
JP6678582B2 (ja)	2020-04-08
PH12015502718A1 (en)	2016-03-14
WO2015024666A1 (en)	2015-02-26
KR20160042935A (ko)	2016-04-20
ES2759910T3 (es)	2020-05-12
EA201600189A1 (ru)	2016-08-31

Publication	Publication Date	Title
DK3035955T3 (da)	2019-12-02	Sammensætning og vaccine til behandling af lungekræft
DK3178849T3 (da)	2019-07-01	Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
PL3283527T3 (pl)	2021-06-14	Leczenie skojarzone nowotworów
DK3033086T3 (da)	2022-01-03	Kombinationsterapi til behandling af cancer
PL3377516T3 (pl)	2022-10-10	Kompozycja do leczenia nowotworu
DK3035926T3 (da)	2020-08-31	Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK3129018T3 (da)	2020-01-20	Behandling af NAFLD og NASH
DK2961831T3 (da)	2020-09-07	Sammensætninger og fremgangsmåder til immunterapi
DK3008168T3 (da)	2020-05-04	Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3019200T3 (da)	2022-06-20	Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK2941258T3 (da)	2019-12-16	Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
DK2994533T3 (da)	2019-07-01	Fremgangsmåder og sammensætninger til behandling af cancer
DK3049056T3 (da)	2019-07-29	Topisk antisvampesammensætning og fremgangsmåder til behandling
DK2818481T3 (da)	2019-10-14	Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK3076976T3 (da)	2020-12-07	Fremgangsmåder til behandling af cancer
DK3007695T3 (da)	2024-03-18	Sammensætninger og fremgangsmåder til behandling af anæmi
DK3102200T3 (da)	2023-05-22	Terapeutisk forbindelse og sammensætning
DK3076972T3 (da)	2022-01-03	Cancerbehandling med kombination af plinabulin og taxan
DK3366307T3 (da)	2021-11-01	Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
PL3200815T3 (pl)	2021-10-18	Sposoby i kompozycje do leczenia nowotworu
DK2994157T3 (da)	2020-08-24	Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3828203T3 (da)	2024-07-15	Sammensætninger og fremgangsmåder til behandling af fedtvævsopbygning
DK3033081T3 (da)	2021-05-31	Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
DK3024428T3 (da)	2021-01-18	Sammensætninger og fremgangsmåder til dental mineralisering
DK3511004T3 (da)	2024-09-23	Kombineret præparat til behandling af cancer